| scholarly article | Q13442814 |
| P2093 | author name string | Li Wang | |
| Rui Xu | |||
| Richard W Compans | |||
| Elena V Vassilieva | |||
| Bao-Zhong Wang | |||
| Andrei N Vzorov | |||
| Jadranka Bozja | |||
| Ying-Chun Wang | |||
| P2860 | cites work | Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. | Q38554957 |
| Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 | Q39612212 | ||
| Measuring HIV neutralization in a luciferase reporter gene assay | Q39914262 | ||
| Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity | Q39934862 | ||
| Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays | Q39988991 | ||
| Injection of flagellin into the host cell cytosol by Salmonella enterica serotype Typhimurium | Q40073247 | ||
| A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity | Q40138835 | ||
| Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity | Q40232989 | ||
| Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes | Q40641430 | ||
| Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses | Q40763973 | ||
| Human immunodeficiency virus-like particles activate multiple types of immune cells. | Q42034526 | ||
| Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity | Q45732207 | ||
| Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. | Q50060542 | ||
| Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. | Q50096687 | ||
| Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine | Q50128234 | ||
| Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. | Q51890555 | ||
| Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization. | Q54512499 | ||
| Bacterial flagellin is an effective adjuvant for CD4+ T cells in vivo | Q56904232 | ||
| Selection of recombinant vaccinia viruses on the basis of plaque formation | Q71866680 | ||
| Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts | Q22251065 | ||
| Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility | Q28185475 | ||
| TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system | Q28240172 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. | Q30359424 | ||
| Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. | Q30372024 | ||
| Advances in vaccine adjuvants | Q33764666 | ||
| Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis | Q34334406 | ||
| A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants | Q34678990 | ||
| B lymphocytes: how they develop and function. | Q34813171 | ||
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
| The Role of Mucosal Immunity in Prevention of HIV Transmission | Q35109057 | ||
| Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. | Q35277985 | ||
| A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses | Q35569049 | ||
| Virus-like particles as HIV-1 vaccines | Q35918111 | ||
| Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins | Q35985896 | ||
| Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles | Q36099235 | ||
| A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. | Q36149102 | ||
| Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. | Q36464264 | ||
| Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. | Q36600380 | ||
| Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation | Q36685254 | ||
| Implication of nanoparticles/microparticles in mucosal vaccine delivery | Q36837152 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Prospects of HIV Env modification as an approach to HIV vaccine design | Q37017780 | ||
| HIV-1 neutralization: mechanisms and relevance to vaccine design | Q37017819 | ||
| Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface | Q37211421 | ||
| Strategies for optimizing targeting and delivery of mucosal HIV vaccines | Q37554135 | ||
| P433 | issue | 1 | |
| P304 | page(s) | e00328-10 | |
| P577 | publication date | 2011-02-15 | |
| P1433 | published in | mBio | Q15817061 |
| P1476 | title | Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant | |
| P478 | volume | 2 |
| Q40578582 | Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model |
| Q38252451 | Adjuvants for foot-and-mouth disease virus vaccines: recent progress |
| Q38417265 | Advances and challenges in mucosal adjuvant technology |
| Q64887149 | Advantages and Limitations of Integrated Flagellin Adjuvants for HIV-Based Nanoparticle B-Cell Vaccines. |
| Q37505389 | Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization |
| Q38634734 | Bacterial flagellin-a potent immunomodulatory agent. |
| Q34587023 | Cell death and serum markers of collagen metabolism during cardiac remodeling in Cavia porcellus experimentally infected with Trypanosoma cruzi |
| Q37018558 | Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses |
| Q26775082 | Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection |
| Q52729536 | DNA Vaccine-Encoded Flagellin Can Be Used as an Adjuvant Scaffold to Augment HIV-1 gp41 Membrane Proximal External Region Immunogenicity. |
| Q38081965 | Developments in virus-like particle-based vaccines for HIV. |
| Q37951525 | Developments in virus-like particle-based vaccines for infectious diseases and cancer |
| Q40835166 | Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines |
| Q37587048 | Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway |
| Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
| Q41148377 | Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin |
| Q39537395 | In Silico and In Vitro Studies of Truncated Forms of Flagellin (FliC) of Enteroaggregative Escherichia coli (EAEC). |
| Q39231806 | In silico study of ligand binding site of toll-like receptor 5. |
| Q35824686 | Incorporation of a GPI-anchored engineered cytokine as a molecular adjuvant enhances the immunogenicity of HIV VLPs |
| Q88424541 | Incorporation of membrane-anchored flagellin into Salmonella Gallinarum bacterial ghosts induces early immune responses and protection against fowl typhoid in young layer chickens |
| Q30357830 | Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity |
| Q38330161 | Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization |
| Q92889493 | Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission |
| Q38727453 | Mucosal vaccine delivery: Current state and a pediatric perspective |
| Q37971867 | Neutralizing antibodies and control of HIV: moves and countermoves. |
| Q52593221 | Recombinant porcine reproductive and respiratory syndrome virus expressing membrane-bound IL-15 as immunomodulatory adjuvant enhances NK and γδ T cell responses and confers heterologous protection. |
| Q54207383 | Sequential immunizations with a panel of HIV-1 Env virus-like particles coach immune system to make broadly neutralizing antibodies. |
| Q34778787 | The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon |
| Q36018410 | Utilizing a TLR5-Adjuvanted Cytomegalovirus as a Lentiviral Vaccine in the Nonhuman Primate Model for AIDS. |
| Q38166277 | Utilizing bacterial flagellins against infectious diseases and cancers |
| Q52655238 | Virus-Like Particle, Liposome, and Polymeric Particle-Based Vaccines against HIV-1. |
| Q30421558 | Virus-like particles as universal influenza vaccines |
| Q37101184 | Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice |
Search more.